Who is sponsoring NCT07324421?

NCT07324421 is sponsored by Resolve Stroke.

What drugs are being tested in NCT07324421?

Interventions in NCT07324421: Ultrasound contrast agent (Contrast-enhanced ultrasound).

What condition does NCT07324421 study?

NCT07324421 studies Neuro ICU, Sub Arachnoid Hemorrhage, Neurological Complication, Cerebral Ischemia, Brain Injuries, Vascular.

Is NCT07324421 still recruiting?

NCT07324421 is currently recruiting now. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT07324421: SCULPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT

Recruiting now NA Last updated 7 January 2026

What this trial tests

NA trial testing Ultrasound contrast agent (Contrast-enhanced ultrasound) in Neuro ICU in 50 participants. Currently enrolling.

Timeline

25 October 2025

Primary endpoint
4 June 2026

15 August 2026

Quick facts

Lead sponsor	Resolve Stroke
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	25 October 2025
Primary completion	4 June 2026
Estimated completion	15 August 2026
Sites	1 location across France

Drugs / interventions tested

Ultrasound contrast agent (Contrast-enhanced ultrasound) — full drug profile →

Conditions studied

Neuro ICU — all drugs for Neuro ICU →
Sub Arachnoid Hemorrhage — all drugs for Sub Arachnoid Hemorrhage →
Neurological Complication — all drugs for Neurological Complication →
Cerebral Ischemia — all drugs for Cerebral Ischemia →

Sponsor

Resolve Stroke

Who can join

18 and older, any sex, with Neuro ICU or Sub Arachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal monitoring using biophysical, electrophysiological, and imaging data is essential. In patients with subarachnoid hemorrhage (SAH), the most frequent and severe complication is delayed cerebral ischemia, often linked to arterial vasospasm and potentially leading to infarction. Early diagnosis combines transcranial Doppler (TCD), sensitive to vasospasm, with perfusion CT (CTP), which measures cerebral perfusion; this approach guides therapy and improves prognosis. Ultrasound, especially when enhanced with contrast agents (CEUS), allows non-invasive, bedside, repeated visualization of cerebral blood flow and perfusion-even through the skull. Agents like SonoVue® help quantify perfusion using time-intensity curves. The study aims to assess whether cerebral perfusion measurements from the SYLVER device are equivalent to those from CTP in ICU or CCU patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07324421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Resolve Stroke
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07324421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing